Media Coverage

Enveric Biosciences has received a Notice of Allowance (NoA) from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the company’s new chemical entity (NCE)…

But perhaps, most importantly, says Kevin Coveney, CFO at Enveric Biosciences, is that the CFO needs to understand their role as a support to the CEO in realising their plans.…

Thanks to the Golden Triangle, Britain is great at biotech innovation, it’s just not that good at nurturing this innovation through to the blue-chip stage. This can be attributed to…

A Boston-area biotechnology firm announced it has received a patent titled “Carboxylated Psilocybin Derivatives and Methods of Using” for its EVM301 series of molecules to treat a range of mental…

Ahead of the competition, drug developers are locking in patents while the psychedelic renaissance takes the medical community by storm. Full Article

The psychedelic drug MDMA edges closer towards FDA approval for the treatment of post-traumatic stress disorder (PTSD) in the U.S., after promising results of a trial were published. This comes…

The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series…

Enveric Biosciences (NASDAQ: ENVB) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company’s…

https://www.benzinga.com/general/biotech/22/04/26693851/exclusive-enveric-offers-investors-rare-exposure-to-both-cannabis-and-psychedelic-industries